T. V. Klimenko

T. V. Klimenko

Auto-generated profile, based on publicly available information

T. V. Klimenko

National Research Center on Addictions – branch of V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology ; All-Russian State University of Justice

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Суицидология
Verified
Journal Article
Closed access
ТКТ.в. Клименко
Т.в. Клименко
АКА.а. Козлов
А.а. Козлов
БПБ.с. Положий
Б.с. Положий
СИС.а. Игумнов
С.а. Игумнов
АИА.л. Игонин
А.л. Игонин
АША.д. Шустов
А.д. Шустов

1 January 2021 in Вопросы наркологии
Verified
Journal Article
Closed access
TKT.V. Klimenko
T.V. Klimenko
MAM.L. Arkus
M.L. Arkus
NEN.N. Eroshchenko
N.N. Eroshchenko
ISI.V. Senshinov
I.V. Senshinov
AEAlexander Eganov
Alexander Eganov
NVN.I. Visyagin
N.I. Visyagin
Представлены результаты исследования чувствительности и специфичности теста карбогидрат-дефицитного трансферрина (CDT) в отношении хронического употребления алкоголя у 129 пациентов с алкогольной зависимостью, которые в течение минимум двух недель ежедневно употребляли алкоголь в дозах, вызывающих состояние опьянения. Полученные данные сопоставлялись с результатами теста от 32 условно здоровых добровольцев, в отношении которых были получены достоверные сведения об отсутствии хронического употребления алкоголя. Установлено, что чувствительность данного теста находится в диапазоне от 65,89 до 74,42%, что не может считаться достаточным для целей юридически значимых ситуаций, требующих идеального маркера с чувствительностью, приближающейся к 100%. Установленную близкую к 100% специфичность теста предлагается рассматривать как относительную, поскольку установленные для исследования строгие критерии отбора (мужской пол и отсутствие заболеваний печени и сахарного диабета) существенно сужают ее диагностическую...


31 October 2026 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Verified
Journal Article
Open access
PDF file
FSFarid Shagiakhmetov
Farid Shagiakhmetov
YSYu. M. Scheidegger
Yu. M. Scheidegger
EKEvgeny Krupitsky
Evgeny Krupitsky
TKT. V. Klimenko
T. V. Klimenko
SGS. E. Golygina
S. E. Golygina
АСА. В. Сахаров
А. В. Сахаров
Gambling disorder (GD) is a behavioral addiction characterized by high comorbidity, significant social and economic consequences. The neurobiological mechanisms underlying GD are similar to those observed in substance use disorders, which opens possibilities for pharmacological intervention. However, no medication has yet been approved for the treatment of GD, and the evidence base for existing agents remains limited. This review summarizes data on the pharmacological treatment of GD based on current systematic reviews and network meta-analyses, and discusses methodological limitations and clinical prospects for the use of various drug classes. This narrative literature review was conducted, encompassing clinical trials, case series, and open-label studies of opioid antagonists, antipsychotics, mood stabilizers, anticonvulsants, antidepressants, gabapentinoids, and other agents. The most compelling evidence was found for nalmefene and naltrexone, which produced statistically significant reductions in GD symptoms compared to placebo, particularly in patients with high craving. Antidepressants, olanzapine, and topiramate failed to outperform placebo in most studies. Mood stabilizers may be beneficial in cases of comorbid bipolar disorder, but the evidence remains very limited. N-acetylcysteine, memantine and gabapentinoids showed encouraging preliminary results; GLP-1 receptor agonists, ketamine, and psilocybin remain experimental. Thus, opioid antagonists may be considered a first-line (off-label) therapy for GD, complementing rather than replacing cognitive-behavioral therapy. Larger controlled trials and the identification of biomarkers for treatment personalization are needed.

15 October 2025 in National Health Care (Russia)
Verified
Journal Article
Open access
PDF file
SSS. V. Shport
S. V. Shport
AKA. A. Kozlov
A. A. Kozlov
RAR. V. Akhapkin
R. V. Akhapkin
KSK. N. Shaklein
K. N. Shaklein
TKT. V. Klimenko
T. V. Klimenko
EFE. V. Fadeeva
E. V. Fadeeva
Post-traumatic stress disorder (PTSD) is a condition that occurs in direct participants of potentially traumatic events, such as natural or man-made disasters, physical or sexual violence, combat, accidents, and is characterized by obsessive re-experiencing of such events. Effective medical care for patients with PTSD requires not only individualized approach but also a well-structured organizational and methodological framework. This article reviews key aspects of organizing medical care for patients with PTSD, new approaches to early detection, treatment, and rehabilitation. Aim. Analysis of organizational and methodological aspects of providing specialized psychiatric and narcological care to patients with PTSD in the Russian Federation and other countries and to present an innovative psychosocial and medical rehabilitation program. Materials and methods. Based on comprehensive approach to studying the problem, a new organizational and methodological model of providing medical care to patients with PTSD was developed. It includes a comprehensive medical and psychosocial rehabilitation program developed by specialists of the V.P. Serbsky National Medical Research Center for Psychiatry and Narcology of the Russian Federation Ministry of Health. The rehabilitation program was tested in 2024 at the center’s branches: Moscow Research Institute of Psychiatry, the National Research Centre on Addictions, and the Khmolino Clinical Rehabilitation Center. Results. The methodological basis for developing the program included legal, organizational and economic foundations for protecting citizens’ health; clinical guidelines; national guidelines on psychiatry, psychotherapy and narcology; analysis of Russia’s and other countries’ experience in providing care to individuals with PTSD. The presented organizational and methodological model for providing specialized psychiatric and narcological care for patients with PTSD and comorbid disorders is based on comprehensive, rather than frequently used sequential approach. Conclusion. Given the diversity of traumatic factors, of clinical manifestations of PTSD, and its course, as well as the high incidence of comorbid mental, substance abuse, and somatic disorders, a shift from a sequential model of patient management to a comprehensive approach is needed. This will facilitate higher treatment adherence and maximize therapeutic effectiveness. Key factors for success also include development of a unified methodology and conceptual framework to apply screening techniques and early motivational interventions, specialist training, and introducing advanced innovative technologies into medical practice.

5 October 2026 in Сибирский вестник психиатрии и наркологии
Verified
Journal Article
Closed access
ASA.V. Sakharov
A.V. Sakharov
TKT.V. Klimenko
T.V. Klimenko
SGS.E. Golygina
S.E. Golygina
TKT.A. Kozhinova
T.A. Kozhinova
MAM.L. Arkus
M.L. Arkus
AKA.A. Kozlov
A.A. Kozlov